908 Devices Q2 revenue up 14% YoY, raises FY25 revenue outlook.

• 908 Devices reports 14% revenue growth from continuing operations. • Q2 revenue from continuing operations exceeds expectations. • Company raises 2025 revenue outlook. • 908 Devices announces record XplorIR placements. • VipIR launched successfully. • Progress made on path to profitability. • Company confident in hitting revenue and adjusted EBITDA targets.

Boston, MA – 908 Devices Inc. (Nasdaq: MASS), a leading provider of purpose-built handheld chemical analysis tools, has reported strong financial results for the second quarter of 2025. The company's revenue from continuing operations grew by 14% year-over-year, reaching $13.0 million [1].

The company's CEO and Co-founder, Kevin J. Knopp, highlighted the company's achievements during the quarter. "We executed with urgency and discipline in the second quarter, driving strong top-line growth while advancing key structural initiatives to strengthen our financial profile," said Knopp. "We delivered record XplorIR placements, successfully launched VipIR, and made meaningful progress on our path to profitability."

908 Devices exceeded its own expectations for Q2 2025, with revenue from continuing operations surpassing the previous outlook. The company also announced a revised 2025 revenue outlook, expecting full-year revenues from continuing operations to range between $54 million and $56 million, up from the previous guidance of $53 million to $55 million [1].

The company's adjusted gross margin for the second quarter was 56%, a decrease of approximately 220 basis points compared to the prior year period. This decrease was primarily driven by an increase in warranty costs related to the growing installed base and specific costs incurred in the second quarter of 2025. Operating expenses increased to $21.5 million, up from $14.7 million in the prior year period, primarily due to a $6.8 million non-cash charge for the change in fair value of the contingent consideration liability, $1.0 million in facility shutdown and restructuring costs, and the inclusion of operating expenses related to the RedWave Technology acquisition [1].

Despite the increase in operating expenses, 908 Devices remains confident in its ability to hit both its revenue and adjusted EBITDA targets for 2025. The company's strong performance in the second quarter, including record XplorIR placements and the successful launch of the VipIR handheld chemical analyzer, reinforces this confidence. Additionally, the company's progress on its path to profitability and the improving funding landscape in the U.S. and globally set a durable foundation for long-term growth and expanding demand for its handheld solutions through 2026 and beyond [1].

908 Devices will host a conference call to discuss the second quarter 2025 financial results before market open on Tuesday, August 5, 2025, at 5:30 am Pacific Time / 8:30 am Eastern Time. A webcast of the conference call can be accessed at [ir.908devices.com/news-events/events](https://ir.908devices.com/news-events/events) [1].

References:
[1] [https://www.stocktitan.net/news/MASS/908-devices-reports-second-quarter-2025-financial-results-and-raises-gjqhoyl8lmpi.html](https://www.stocktitan.net/news/MASS/908-devices-reports-second-quarter-2025-financial-results-and-raises-gjqhoyl8lmpi.html)